Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio Page 1

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical precision oncology company, today announced the strategic reprioritization of its research and development activities to focus its efforts on advancing its portfolio of clinical oncology programs. With multiple upcoming clinical milestones and potential registrational studies in the near term, the Company is streamlining its operations to focus on advancing its lunresertib, camonsertib, RP-1664 and RP-3467 programs, while significantly reducing the size of its preclinical research and discovery activities.

“Today, we recognize the extraordinary contributions and productivity of our discovery team, which has enabled the development of our deep, innovative clinical portfolio. In our mission to rapidly develop novel, practice-changing therapies, we will more fully focus our resources on our most promising and advanced precision oncology programs to maximize value for patients and our shareholders,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “We remain on track to report data from our MYTHIC dose expansion study evaluating lunresertib in combination with camonsertib in patients with ovarian and uterine cancer in the fourth quarter of 2024, with the potential to initiate a registrational study in 2025.”